Efficacy and cytotoxicity of a liver-targeted nitric oxide-releasing drug in the treatment of liver injury in mice
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 15
- DOI:
- 10.3969/j.issn.1009-3079.2010.15.012
- Key Word:
- 肝靶向治疗;一氧化氮;胆酸;偶合物;肝损伤
Abstract： 目的:评价新型肝靶向一氧化氮释放药物NO-040527抗小鼠肝损伤的药效学及细胞毒性,为进一步的临床前研究开发奠定基础.方法:通过腹腔注射四氯化碳、D-氨基半乳糖或对乙酰氨基酚,制备肝损伤动物模型;分别于造模前1 h和造模后12 h灌胃给予不同剂量的待测药物,于第2次给药后24 h,眼眶取血,留取血清标本,测定血清中的ALT,AST水平.取对数生长期的HepG2细胞,接种于96孔培养板,长成单层,加入不同浓度的待测药物.继续培养24 h,用MTT法,测定细胞的存活率.结果:肝靶向药物NO-040527能够显著降低CC14所致小鼠肝损伤的转氨酶升高(P<0.01),降酶作用具有良好的剂量依赖性;在相同剂量(55 mg/kg)下,NO-040527的降酶作用强于阳性对照药NCX-1000(P<0.05).同样,肝靶向药物NO-040527能够显著降低对乙酰氨基酚所引起的小鼠转氨酶升高(P<0.01),各剂量组之间降酶作用无显著性差异,在相同剂量(55 mg/kg)下,NO-040527的降酶作用与NCX-1000相当.NO-040527对D-氨基半乳糖所致小鼠肝损伤没有保护作用,中低剂量组的小鼠血清ALT、AST值较模型组相比没有显著差异,高剂量组转氨酶甚至略高于模型组.NO-040527在500 μmol/L浓度显示出细胞毒性,细胞存活率为45.96%±29.46%(P=0.058);在1 000 μmol/L浓度具有显著的细胞毒性(P<0.005);在50 μmol/L和100 μmol/L浓度时,NO-040527显示出促细胞生长的作用,细胞存活率分别为137.67%±8.47%和152.65%±10.084%,显著高于溶剂组(P<0.05).结论:NO-040527能够显著降低CCl4和对乙酰氨基酚所引起的小鼠转氨酶升高,但NO-040527和NCX-1000对D-氨基半乳糖所致小鼠肝损伤没有保护作用,高剂量甚至加重转氨酶升高.NO-040527在高浓度显示出细胞毒性,低浓度显示出促细胞生长的作用.
- [1]靳雪源,张玲霞,楼敏,等.肝靶向基因给药系统AsOR-PL+PEG-PEl的研究[J].2002,(3).
- [2]马骁,刘冰熔.门静脉高压药物治疗的新进展[J].2008,(33).
- [3]靳雪源,王惠芬.肝靶向胆酸-脂肪酸偶合物的研究进展[J].2008,(33).
- [4]孙群,张强,朱金水,等.一氧化氮、白介素、肿瘤坏死因子与肝硬化患者预后的关系[J].2007,(6).
- [5]A, Morikawa,Y, Kato,T, Sugiyama,etc.Role of nitric oxide in lipopolysaccharide-induced hepatic injury in D-galactosamine-sensitized mice as an experimental endotoxic shock model.[J].1999,67.
- [6]T K, Gupta,M, Toruner,M K, Chung,etc.Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats.[J].1998,28.
- [7]黄正明,杨新波.抗肝炎中药现代研究与应用[M].2006.
- [8]Jaime Bosch,Juan C. García-Pagán,Faust Feu,etc.New approaches in the pharmacologic treatment of portal hypertension[J].1993,17(1).
- [9]Fiorucci S,Antonelli E,Tocchetti P,etc.Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.[J].2004,22(2).
- [10]Boyer JL,Trauner M.Bile salt transporters: molecular characterization, function, and regulation.[J].2003,83(2).
- [11]Lanza M,Pariali M,Busi C,etc.Doxorubicin coupled to lactosaminated albumin: Effects on rats with liver fibrosis and cirrhosis.[J].2006,38(6).
- [12]Bijsterbosch MK,de-Clercq E,Ying C,etc.Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethyl)adenine against hepatitis B virus.[J].2001,60(3).
- [13]Miquel Navasa,Jaime Bosch,Jürg Reichen,etc.Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension[J].1988,8(4).
- [14]Wiest R,Groszmann RJ.Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance.[J].1999,19(4).
- [15]David A, Sass,Parke, Chang,Kapil B, Chopra.Nonalcoholic fatty liver disease: a clinical review.[J].2005,50(1).
- [16]Fiorucci S,Brancaleone V,Baldoni M,etc.NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver.[J].2003,39(6).
- [17]Angus PW,Lubel JS.Modern management of portal hypertension.[J].2005,35(1).
- [18]Rosa A,Cohen M,Lefton HB.Diagnosis and epidemiology of cirrhosis.[J].2009,93(4).
- [19]J M, Salmerón,L, Ruiz del Arbol,A, Ginès,etc.Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis.[J].1993,17.